HemOnc vocabulary relationships
The purpose of this page is to describe the existing relationships in the HemOnc ontology and to give examples. Most of the examples are based on adjuvant CapeOx for colon cancer, as described in the XELOXA study's primary publication (Schmoll et al. 2007, JCO). You can also follow this link to the Concepts page.
Common internal relationships and examples
These relationships occur at least 100 times in the most recent version of the ontology. This table is sortable; the default arrangement is alphabetical by relationship type. Note that in the actual relationship table, the HemOnc concept code is used, not the concept name as is shown here for clarity. For simplicity, relationships to regimen stubs or sig stubs are not shown, even if they occur more than 100 times.
| Concept Type 1 | Relationship | Concept Type 2 | Example 1 | Relationship | Example 2 |
|---|---|---|---|---|---|
| Study | Began enrollment in | Year | XELOXA | Began enrollment in | 2003 |
| Regimen | Can be followed by | Regimen | 7 plus 3i (induction) (HO:1095) | Can be followed by | HiDAC (consolidation) (HO:839) |
| Regimen | Can be followed by | Procedure | FEC (neoadjuvant) | Can be followed by | Surgery |
| Regimen | Can be preceded by | Regimen | HiDAC (consolidation) (HO:839) | Can be preceded by | 7 plus 3i (induction) (HO:1095) |
| Regimen | Can be preceded by | Procedure | CapeOx (adjuvant) | Can be preceded by | Surgery |
| Study | Ended enrollment in | Year | XELOXA | Ended enrollment in | 2004 |
| Component | Has accepted use | Condition | Capecitabine | Has accepted use | Colon cancer |
| Regimen | Has accepted use | Condition | CapeOx | Has accepted use | Colon cancer |
| Regimen | Has immunosuppressor | Component | Dexamethasone monotherapy | Has immunosuppressor | Dexamethasone |
| Regimen | Has local therapy | Component | IT Cytarabine & Methotrexate | Has local therapy | Cytarabine |
| Regimen | Has supportive med | Component | Carboplatin & Pemetrexed | Has supportive med | Dexamethasone |
| Regimen | Has supportive med | Component Class | Bortezomib monotherapy | Has supportive med | Bisphosphonate |
| Regimen | Has been compared to | Regimen | CapeOx | Has been compared to | FULV |
| Component | Has brand name | Brand Name | Capecitabine | Has brand name | Xeloda |
| Regimen | Has context | Context | CapeOx | Has context | Adjuvant therapy |
| Component | Has FDA indication | Condition | Capecitabine | Has FDA indication | Colon cancer |
| Component | Has FDA labeling | Context | Erlotinib | Has FDA labeling | Mutation-specific |
| Reference | Has first author | Author | XELOXA::00 | Has first author | Schmoll_Hans Joachim |
| Reference | Has middle author | Author | XELOXA::00 | Has middle author | Tabernero_Jose M |
| Reference | Has last author | Author | XELOXA::00 | Has last author | Haller_Daniel G |
| Regimen | Has min cycle length | Duration | CapeOx | Has min cycle length | 21 days |
| Regimen | Has max cycle length | Duration | CapeOx | Has max cycle length | 21 days |
| Regimen | Has min cycle num | Numeric | CapeOx | Has min cycle num | 1 |
| Regimen | Has max cycle num | Numeric | CapeOx | Has max cycle num | Indefinite |
| Regimen | Has min duration | Numeric | CapeOx | Has min duration | 21 days |
| Regimen | Has max duration | Numeric | CapeOx | Has max duration | Indefinite |
| Regimen | Has modality | Modality | CapeOx | Has modality | Chemotherapy |
| Reference | Has PMID | PubMedURL | XELOXA::00 | Has PMID | https://pubmed.ncbi.nlm.nih.gov/17194911 |
| Reference | Has URL | ReferenceURL | XELOXA::00 | Has URL | https://doi.org/10.1200/jco.2006.08.1075 |
| Reference | Has title | ReferenceTitle | XELOXA::00 | Has title | Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients |
| Regimen | Is current in | Condition | CapeOx | Is current in | Colon cancer |
| Regimen | Is historical in | Condition | Edrecolomab monotherapy | Is historical in | Colon cancer |
| Component | Was FDA approved | Year | Capecitabine | Was FDA approved | 1998 |
| Reference | Was published in | Journal | XELOXA::00 | Was published in | J Clin Oncol |
| Reference | Was published year | Year | XELOXA::00 | Was published year | 2007 |
| Regimen | Has cycle | Cycle Sigs | CapeOx | Has cycle | 21-day cycle for 8 cycles |
| Study | Has reference | Reference | XELOXA | Has reference | XELOXA::00 |
| Study | Has reported endpt | Endpoint | XELOXA | Has reported endpt | OS |
| Study | Had experimental design | Experimental design | XELOXA | Had experimental design | In-class switch |
| Component | Has route | Route | Capecitabine | Has route | PO |
| Study | Has study group | Study Group | ECOG E3200 | Has study group | Eastern Cooperative Oncology Group |
| Study | Has study type | Study Class | X-ACT | Has study type | FDA registration study |
| Component | Has sig | Sig | Capecitabine | Has sig | 1000 mg/m^2 PO twice per day on days 1 to 14 |
| Component | Is a | Component Class | Capecitabine | Is a | Fluoropyrimidine |
| Component Class | Is a | Component Class | Fluoropyrimidine | Is a | Pyrimidine analogue |
| Condition | Is a | Condition | Colon cancer | Is a | Colorectal cancer |
| Regimen | Is a | Regimen Class | CapeOx | Is a | Platinum doublet |
| Component | May have route | Route | Dexamethasone | May have route | PO |
| Regimen | Was studied in | Study | CapeOx | Was studied in | XELOXA |
| Context | Was studied in | Study | Adjuvant therapy | Was studied in | XELOXA |
| Condition | Was studied in | Study | Colon cancer | Was studied in | XELOXA |
Uncommon internal relationships and examples
These relationships occur less than 100 times in the most recent version of the ontology. This list is currently incomplete.
| Concept Type 1 | Relationship | Concept Type 2 | Example 1 | Relationship | Example 2 |
|---|---|---|---|---|---|
| Regimen | Has antineoplastic | Component | CapeOx | Has antineoplastic | Capecitabine |
| Context | Is a | Context | Adjuvant therapy | Is a | Post-definitive therapy |
| Regimen | Has immunosuppressor | Component Class | Fludarabine & Melphalan | Has immunosuppressor | ATG (type not specified) |
| Regimen | Has been compared to | Procedure | Cisplatin, Fluorouracil, RT | Has been compared to | Surgery |
| Regimen | Has been compared to | Regimen Class | Ipilimuamb & Nivolumab | Has been compared to | Platinum doublet |
Common external relationships and examples
These relationships occur at least 100 times in the most recent version of the ontology.
| Concept Type 1 | Relationship | Concept Type 2 | Example 1 | Relationship | Example 2 |
|---|---|---|---|---|---|
| Regimen | Has antineopl Rx | RxNorm CUI | CapeOx | Has antineopl Rx | 194000 |
| Regimen | Has immunosuppr Rx | RxNorm CUI | Dexamethasone monotherapy | Has immunosuppr Rx | 3264 |
| Regimen | Has local therap Rx | RxNorm CUI | CHOP-14 | Has local therap Rx | 3041 |
| Regimen | Has support med Rx | RxNorm CUI | Carboplatin & Pemetrexed | Has support med Rx | 3264 |
| Component | Maps to | RxNorm CUI | Capecitabine | Maps to | 194000 |
| Condition | Maps to | NCIT CUI | Colon cancer | Maps to | C4910 |
Uncommon external relationships and examples
These relationships occur less than 100 times in the most recent version of the ontology.
| Concept Type 1 | Relationship | Concept Type 2 | Example 1 | Relationship | Example 2 |
|---|---|---|---|---|---|
| Regimen | Has antineopl Rx | RxNorm Extension CUI | Pixantrone monotherapy | Has antineopl Rx | OMOP997118 |
| Component | Maps to | RxNorm Extension CUI | Pixantrone | Maps to | OMOP997118 |
Further explanation of some relationships
Can be followed by
This directed relationship is phrased as an optional because there is always the possibility, even in a pre-defined protocol, that the patient will not go on to receive the second (or third, etc.) part of a treatment protocol.
Can be preceded by
This directed relationship is phrased as an optional because it is contextual; in many treatment contexts it is not necessary that the first treatment occurs before the second. In some treatment contexts the relationship is absolute, e.g., chemotherapy given in the adjuvant setting must by definition be preceded by a surgical procedure. This subtle distinction is not yet captured by the ontology.
Has been compared to
This non-directional relationship is the pairwise comparison of two regimens in a randomized clinical trial. In the most common scenario one regimen is a control arm and the other is experimental arm, although this is not always the case.
Has FDA indication
With very few exceptions, the FDA approves drugs, not regimens. Currently, all of these relationships in HemOnc are between components (drugs) and conditions.
Has FDA labeling
Most oncology labels issued by the FDA have specific contextual restrictions, which we are beginning to incorporate into HemOnc. Initially, we are focusing on labels that have a protein-expression or gene mutation requirement, i.e., a biomarker requirement. For example, the drug Erlotinib (Tarceva) is approved for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutations.
Has reported endpt
For "negative" studies, which we define as those having p>0.10 regardless of the predeclared level of alpha, the reported endpoint is the primary endpoint. For "positive" studies, the reported endpoint is that which is the least surrogate with a p<0.10.
Has route and May have route
Components with only one route of administration are related to that route using "Has route". Conversely, components with multiple routes of administration are related to those routes using "May have route".
Has study type
Right now there is only one defined study class: FDA registration trials. We will plan to expand this in the near future to include details such as phase of study, whether a study was a cooperative group trial, etc.
Was replaced by
This is a special relationship type used to associate current and deprecated concepts. For example, "Imatinib monotherapy, high dose" has been replaced by "Imatinib monotherapy" and the replacement is captured by this relationship.